Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Mar 1;142(5):323-32.
doi: 10.7326/0003-4819-142-5-200503010-00007.

The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance

William H Herman  1 , Thomas J Hoerger, Michael Brandle, Katherine Hicks, Stephen Sorensen, Ping Zhang, Richard F Hamman, Ronald T Ackermann, Michael M Engelgau, Robert E Ratner; Diabetes Prevention Program Research Group
Affiliations

The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance

William H Herman et al. Ann Intern Med. .

Abstract

Background: The Diabetes Prevention Program (DPP) demonstrated that interventions can delay or prevent the development of type 2 diabetes.

Objective: To estimate the lifetime cost-utility of the DPP interventions.

Design: Markov simulation model to estimate progression of disease, costs, and quality of life.

Data sources: The DPP and published reports.

Target population: Members of the DPP cohort 25 years of age or older with impaired glucose tolerance.

Time horizon: Lifetime.

Perspectives: Health system and societal.

Interventions: Intensive lifestyle, metformin, and placebo interventions as implemented in the DPP.

Outcome measures: Cumulative incidence of diabetes, microvascular and neuropathic complications, cardiovascular complications, survival, direct medical and direct nonmedical costs, quality-adjusted life-years (QALYs), and cost per QALY.

Results of base-case analysis: Compared with the placebo intervention, the lifestyle and metformin interventions were estimated to delay the development of type 2 diabetes by 11 and 3 years, respectively, and to reduce the absolute incidence of diabetes by 20% and 8%, respectively. The cumulative incidence of microvascular, neuropathic, and cardiovascular complications were reduced and survival was improved by 0.5 and 0.2 years. Compared with the placebo intervention, the cost per QALY was approximately 1100 dollars for the lifestyle intervention and $31 300 for the metformin intervention. From a societal perspective, the interventions cost approximately 8800 dollars and 29,900 dollars per QALY, respectively. From both perspectives, the lifestyle intervention dominated the metformin intervention.

Results of sensitivity analysis: Cost-effectiveness improved when the interventions were implemented as they might be in routine clinical practice. The lifestyle intervention was cost-effective in all age groups. The metformin intervention did not represent good use of resources for persons older than 65 years of age.

Limitations: Simulation results depend on the accuracy of the underlying assumptions, including participant adherence.

Conclusions: Health policy should promote diabetes prevention in high-risk individuals.

PubMed Disclaimer

Figures

Figure
Figure
Simulated cumulative incidence of diabetes among adults with impaired glucose tolerance by the Diabetes Prevention Program treatment group.
See this image and copyright information in PMC

Comment in

References

    1. Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW, et al. The evolving diabetes burden in the United States. Ann Intern Med. 2004;140:945–50.[PMID: 15172919]

    1. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–44.[PMID: 9096977]

    1. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.[PMID: 11333990]

    1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.[PMID: 11832527]

    1. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002;51:2796–803.[PMID: 12196473]

Publication types

MeSH terms